Cargando…
Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity
Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflam...
Autores principales: | Huang, Chaolin, Chen, Yuanhong, Liu, Hang, Yang, Jing, Song, Xuejing, Zhao, Junping, He, Na, Zhou, Chengji J., Wang, Yongping, Huang, Changjiang, Dong, Qiaoxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777769/ https://www.ncbi.nlm.nih.gov/pubmed/29383157 http://dx.doi.org/10.18632/oncotarget.23250 |
Ejemplares similares
-
Murine mammary stem/progenitor cell isolation: Different method matters?
por: Gao, Hui, et al.
Publicado: (2016) -
Celecoxib concentration predicts decrease in prostaglandin E(2 )concentrations in nipple aspirate fluid from high risk women
por: Sauter, Edward R, et al.
Publicado: (2008) -
Celecoxib Improves Host Defense through Prostaglandin Inhibition during Histoplasma capsulatum Infection
por: Pereira, Priscilla Aparecida Tartari, et al.
Publicado: (2013) -
LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles
por: Jin, Yan, et al.
Publicado: (2017) -
Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets
por: Wu, Anqi, et al.
Publicado: (2016)